Glycopeptide Side Effects: What Studies Report

The word glycopeptide appears in two largely separate research literatures, and the safety record differs sharply between them. One is the class of glycopeptide antibiotics — vancomycin, teicoplanin and their derivatives — which have been used clinically for decades and are the subject of dedicated adverse-reaction reviews. The other is the much broader category of glycosylated peptides: naturally derived preparations, engineered constructs and hydrogel materials studied in cells and animals, where clinical tolerability data are generally not available. This page summarises what published studies examined and reported; the chemistry and classification background is covered separately in PeptideU's glycopeptide learning course.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or before making any health decision.

Two literatures, two kinds of evidence

Glycopeptide antibiotics are prescription drugs administered in hospitals, so their adverse effects appear in pharmacovigilance reports, case series, clinical trials and narrative reviews. A 2020 review in Pharmacy was written specifically around glycopeptide hypersensitivity and adverse reactions, indicating that this class generated enough reported reactions to justify a review devoted to the topic (PMID 32326261). A 2015 review in European Review for Medical and Pharmacological Sciences was framed explicitly around the use of vancomycin together with its therapeutic and adverse effects (PMID 25753888).

Research-stage glycopeptides are different. Their published record consists mostly of mechanism studies, in vitro screens, animal models and formal toxicology assays. A 2018 study in Toxicological Research evaluated the genotoxic potential of a glycopeptide preparation designated G-7%NANA, which is a preclinical safety endpoint rather than a description of effects in people (PMID 30057700). Where a compound's literature stops at that stage, the absence of human tolerability data is a fact about the evidence base, not a signal that the compound is well tolerated.

Glycopeptide Antibiotics — Hypersensitivity and Adverse Reactions: What Studies Report

The 2020 Pharmacy review organised the published record on glycopeptide hypersensitivity and adverse reactions, addressing how such reactions have been characterised and distinguished within this antibiotic class (PMID 32326261). Reviews of this kind typically separate immune-mediated hypersensitivity from infusion-related and dose-related phenomena, and the primary source is the appropriate place to read how researchers drew those distinctions for specific agents.

The 2015 vancomycin review covered the same drug from both directions — what it was used for and what adverse effects accompanied that use — and researchers presented the two together rather than treating tolerability as an afterthought (PMID 25753888). Readers looking for the specific organ systems, incidence figures or risk factors described in that review should consult the paper itself; this page does not restate numbers that the verified source record here cannot support.

Why the antibiotic data cannot be transferred to other glycopeptides

Adverse-effect profiles are compound-specific. Vancomycin, teicoplanin and a plant-derived glycopeptide share a structural descriptor but not a pharmacology, a route, a dose range or an exposure history. Studies of teicoplanin derivatives as pan-SARS-CoV-2 entry inhibitors, for example, reported antiviral activity against spike protein–mediated viral entry in laboratory systems — an efficacy finding in a new context, not a transfer of the parent drug's clinical safety record to the derivatives (PMID 36916436). Chemically modified analogues require their own toxicology.

Comparator agents and class context: What Studies Report

Glycopeptide antibiotics are often discussed alongside other anti-Gram-positive agents, and those comparators carry their own documented harms. A 2018 case report in BMJ Case Reports described linezolid-induced pancytopenia in a single patient, illustrating how haematological adverse events for alternative agents have entered the literature through individual case documentation (PMID 30054325). Case reports establish that an event occurred and was attributed by the reporting clinicians; they do not establish frequency.

Exposure duration is another variable that clinical research has examined directly. The How Long study, an open-label randomised controlled phase 4 trial published in The Lancet Haematology in 2017, tested optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (PMID 29153975). Trials of that design exist because the amount of antimicrobial exposure — not only the choice of agent — has been treated by researchers as a modifiable determinant of harm and resistance.

Preclinical glycopeptides: what was measured, and what was not

Several glycopeptides in the recent literature have been studied for protective or immunological effects rather than screened for toxicity in humans.

• A 2025 study in Advanced Science reported that Lycium barbarum glycopeptide alleviated neomycin-induced ototoxicity by inhibiting tryptophan hydroxylase–mediated serotonin biosynthesis (PMID 40135846). The study examined protection against a drug-induced injury model; it was not a human tolerability trial of the glycopeptide itself.
• A 2026 paper in Materials Today Bio described a glycopeptide hydrogel that conferred protection and treatment in sepsis through the recruitment and training of macrophages (PMID 41852883). Researchers framed the work as a materials and immune-mechanism investigation.
• The 2018 genotoxicity study of G-7%NANA applied formal toxicology methodology to a glycopeptide preparation, which is the type of assay used to characterise DNA-damaging potential before any clinical work (PMID 30057700).

None of these constitute human side-effect data. Where a page such as this one would otherwise list adverse events observed in people, the honest statement is that for these specific research glycopeptides, such data were not present in the sources reviewed here.

Formulation research and why tolerability drives it

A recurring theme in the glycopeptide literature is reformulation. Researchers reported conjugating vancomycin to silica-coated magnetic nanoparticles in a 2022 ACS Omega study, a strategy aimed at changing how the antibiotic is delivered and targeted (PMID 36061717). A 2017 study in the European Journal of Pharmaceutical Sciences investigated oral delivery of vancomycin using tetraether lipid liposomes, addressing the long-standing problem that the drug is poorly absorbed from the gastrointestinal tract (PMID 28716758). Delivery work of this kind is generally motivated by exposure control — keeping drug concentrations where they are wanted and away from tissues where harm has been reported.

Manufacturing characterisation matters too. A 2019 review in the Journal of Chromatography B surveyed glycan analysis methods for protein therapeutics, reflecting that the sugar component of a glycosylated molecule is itself a quality attribute that analysts measure (PMID 31063953). For any glycopeptide, differences in glycosylation between batches are part of what determines whether two preparations are actually the same material.

Summary table: what each study examined

How to read the evidence gap

1. Check which glycopeptide is being discussed. Vancomycin's adverse-effect literature says nothing about a plant-derived glycopeptide, and vice versa.
2. Check the species and the setting. Findings from cell assays and animal models describe those systems. Researchers reported them as such.
3. Check whether the endpoint was safety at all. Studies of antiviral activity (PMID 36916436) or macrophage biology (PMID 41852883) measured efficacy-type outcomes, not tolerability.
4. Treat absence as absence. No published human adverse-event data for a given research glycopeptide means the question is unanswered.

What this page does not do

It does not state doses, schedules or protocols for any glycopeptide, and it does not compare products. Prescription glycopeptide antibiotics are administered under clinical supervision, and research-grade glycosylated peptides sold for laboratory work are not approved for human use in any jurisdiction covered by the studies above. Regulatory status is a separate question from what the biology literature reports, and both differ from individual medical circumstances, which only a licensed clinician can evaluate.

References

• Glycopeptide Hypersensitivity and Adverse Reactions (Pharmacy, 2020)
• The use of vancomycin with its therapeutic and adverse effects: a review (European Review for Medical and Pharmacological Sciences, 2015)
• Genotoxicity Study of Glycopeptide (G-7%NANA) (Toxicological Research, 2018)
• Lycium barbarum Glycopeptide Alleviates Neomycin-Induced Ototoxicity by Inhibiting Tryptophan Hydroxylase-Mediated Serotonin Biosynthesis (Advanced Science, 2025)
• A glycopeptide hydrogel confers protection and treatment in sepsis via recruitment and training of macrophages (Materials Today Bio, 2026)
• Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors (Biomedicine & Pharmacotherapy, 2023)
• Silica-Coated Magnetic Nanoparticles for Vancomycin Conjugation (ACS Omega, 2022)
• Oral delivery of vancomycin by tetraether lipid liposomes (European Journal of Pharmaceutical Sciences, 2017)
• Glycan analysis for protein therapeutics (Journal of Chromatography B, 2019)
• Linezolid-induced pancytopenia (BMJ Case Reports, 2018)
• Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study) (The Lancet Haematology, 2017)